NASDAQ · SPRB
Spruce Biosciences, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for SPRB: Nov 9, 2026
Spruce Biosciences, Inc. Common Stock is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-5.76. The reported EPS for the same quarter last year was $-14.58.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-5.76 | $-5.13 | $-6.92 | 3 |
| Dec 2026 | $-5.54 | $-4.38 | $-6.91 | 3 |
| Mar 2027 | $-3.68 | $-3.68 | $-3.68 | 1 |
| Jun 2027 | $-3.37 | $-3.37 | $-3.37 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · Zacks · BNK Invest- Fintel · Sep 17, 8:43 PM EDTLake Street Initiates Coverage of Spruce Biosciences at BuyFintel reports that on September 17, 2026, Lake Street initiated coverage of Spruce Biosciences (NASDAQCM:SPRB) with a Buy recommendation. Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine dis
- RTTNews · Aug 27, 10:18 AM EDTSpruce Launches MPS IIIB Resource Website Ahead Of Planned TA-ERT Study In Q4(RTTNews) – Spruce Biosciences, Inc. (SPRB), a late-stage biopharmaceutical company developing therapies for neurological disorders, announced the launch of MPS3BStudy.com, a resource for families and caregivers of children with Sanfilippo Syndrome Type B (MPS IIIB).
- RTTNews · Aug 24, 9:58 AM EDTSpruce Biosciences Confirms Q4 2026 BLA Submission For TA-ERT Following Positive FDA Meetings(RTTNews) – Spruce Biosciences (SPRB), a late-stage biopharmaceutical company developing therapies for neurological disorders, announced it remains on track to submit a BLA for tralesinidase alfa enzyme replacement therapy (TA-ERT) in the fourth quarter of 2026.
- RTTNews · Aug 12, 10:27 AM EDTSpruce Biosciences Q2 Loss Widens; Names Adrian Quarterl CMO, Jessica Cohen VP – Clinical(RTTNews) – Spruce Biosciences, Inc. (SPRB), reported a deeper second-quarter loss on Wednesday, as operating expenses weighed on results and net loss per share nearly doubled from a year earlier.
- Fintel · Apr 27, 8:04 PM EDTCraig-Hallum Initiates Coverage of Spruce Biosciences (SPRB) with Buy RecommendationFintel reports that on April 27, 2026, Craig-Hallum initiated coverage of Spruce Biosciences (NasdaqCM:SPRB) with a Buy recommendation. Analyst Price Forecast Suggests 249.55% Upside
- RTTNews · Apr 21, 7:46 AM EDTSpruce Biosciences Prices $60 Mln Public Offering Of Shares And Pre-Funded Warrants; Stock Down(RTTNews) – Spruce Biosciences, Inc. (SPRB), a late-stage biopharmaceutical company, priced its previously announced public offering of 1.15 million shares at $50 per share and pre-funded warrants to purchase 50,000 shares of common stock at a purchase price of $49.99 per share.
- RTTNews · Apr 21, 4:58 AM EDTSpruce Biosciences Prices Public Offering To Fund Neuro Therapies(RTTNews) – Spruce Biosciences Inc. (SPRB) announced that it has priced a public offering expected to raise $60 million in gross proceeds to advance its neurological disorder therapies.
- Zacks · Apr 3, 9:55 AM EDTWall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to TradeThe average of price targets set by Wall Street analysts indicates a potential upside of 181.2% in Spruce Biosciences (SPRB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- BNK Invest · Mar 25, 12:07 PM EDTWednesday Sector Leaders: Biotechnology, Precious MetalsIn trading on Wednesday, biotechnology shares were relative leaders, up on the day by about 3.6%. Leading the group were shares of Sarepta Therapeutics, up about 27.3% and shares of Spruce Biosciences up about 19.6% on the day. Also showing relative strength are precious metal
- Zacks · Mar 18, 9:55 AM EDTDoes Spruce Biosciences (SPRB) Have the Potential to Rally 208.32% as Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 208.3% in Spruce Biosciences (SPRB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- RTTNews · Feb 20, 9:27 AM ESTWeekly Buzz: NRXP Sets The Path For NRX-100's NDA; IRON Gets FDA's CRL; TOVX Licenses SYN-020(RTTNews) – The biotech space this week witnessed significant key milestones, including FDA approvals, NDA path-setting meetings, rejections, licensing agreements, and oncology drug acquisitions.
- RTTNews · Feb 18, 9:46 AM ESTSpruce Biosciences Stock Falls 5% Despite Positive Outcomes From Two Recent Type B Meetings With FDA(RTTNews) – Stock of Spruce Biosciences, Inc. (SPRB) is falling about 5 percent during Wednesday morning trading despite announcement of positive outcomes from two recent Type B meetings with the U.S. FDA regarding its planned biologics license application for tralesinidase alfa
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Spruce Biosciences, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.